Brief: Akero Therapeutics to Present Topline Week 96 Results from Phase 2b HARMONY Study
29/02/2024 13:04
Feb 29 (Reuters) - Akero Therapeutics Inc AKRO.O :
* AKERO THERAPEUTICS TO PRESENT TOPLINE WEEK 96 RESULTS FROM
PHASE
2B HARMONY STUDY INVESTIGATING EFRUXIFERMIN IN PATIENTS WITH
PRE-CIRRHOTIC MASH
Source text for Eikon: ID:nGNX3lpwwQ
Further company coverage: AKRO.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Akero Therapeutics
See all newsBrief: Novo Nordisk Completes Acquisition Of Akero Therapeutics
NASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 03:58 AM
NASDAQ TRADE HALT TRADING HALTED; FOR INFORMATION REQUESTED BY NASDAQ AT 07:50 PM
Brief: Germany's Cartel Office Says It Approved Acquisition Of Akero Therapeutics By Novo Nordisk
Brief: Akero Therapeutics Stockholders Approve Acquisition By Novo Nordisk